Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4578 | methylprednisolone Wiki | 1.00 |
| drug4597 | mycophenolic acid Wiki | 1.00 |
| drug4595 | mycophenolate mofetil Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4377 | antithymocyte globulin (rabbit) Wiki | 1.00 |
| drug4391 | belatacept Wiki | 1.00 |
| drug4479 | everolimus Wiki | 1.00 |
| drug313 | Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients Wiki | 1.00 |
| drug4786 | tocilizumab Wiki | 0.71 |
| drug3069 | Prednisone Wiki | 0.41 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.
Description: Definitions: Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection. Acute Antibody Mediated Rejection: Diffusely positive immunostaining staining for C4d, presence of circulating anti-donor antibodies, and morphologic evidence of acute tissue injury. Reference: Banff 2007 Classification Renal Allograft Pathology definition of terms.
Measure: Proportion of participants who remain free of biopsy-proven acute T-cell mediated or antibody-mediated rejection as defined by Banff criteria Time: 6 months post transplantationDescription: Definitions: Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection. Acute Antibody Mediated Rejection: Diffusely positive immunostaining staining for C4d, presence of circulating anti-donor antibodies, and morphologic evidence of acute tissue injury. Reference: Banff 2007 Classification Renal Allograft Pathology definition of terms.
Measure: Proportion of participants who remain free of biopsy-proven acute T-cell mediated or antibody-mediated rejection as defined by Banff criteria Time: 12 months post transplantationDescription: Mechanistic assay. Evaluation of the frequency of circulating Tregs over time.Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY: Frequency of circulating T Regulatory Cells (Tregs) Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantationDescription: Mechanistic assay.Donor-specific suppression activity of recipient Tregs will be measured over time by using irradiated donor peripheral blood mononuclear cells (PBMCs) as stimulators. Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY:T Regulatory Cells (Treg) suppressive activity Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantationDescription: Mechanistic assay that measures the frequency of circulating donor-reactive CD4 conventional T cells, CD8 T cells and Tregs analyzed over time. Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY:Alloreactive T cell frequency Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantationDescription: Methodology: Analysis of gene expression in peripheral blood mononuclear cells (PBMCs) stimulated with donor antigen presenting cells to explore genes implicated in T cell checkpoint inhibition (CTLA-4, SFASL, NFATC1, NFATC2, LAG3 and HAVCR2, as examples). Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY:Expression of T cell checkpoint inhibition related genes Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports